Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3

2009

Article référencé dans le Web of Science WOS:000263416700030

Toure Balde A., Perlaza B.L., Sauzet J.P., Ndiaye M., Aribot G., Tall A., Sokhna Cheikh, Rogier C., Corradin G., Roussilhon C., Druilhe P.

Infection and Immunity, 2009, 77 (3), p. 1189-1196 ISSN 0019-9567

Liver-stage antigen 3 (LSA-3) is a new vaccine candidate that can induce protection against Plasmodium falciparum sporozoite challenge. Using a series of long synthetic peptides (LSP) encompassing most of the 210-kDa LSA-3 protein, a study of the antigenicity of this protein was carried out in 203 inhabitants from the villages of Dielmo (n=143) and Ndiop (n=60) in Senegal (the level of malaria transmission differs in these two villages). Lymphocyte responses to each individual LSA-3 peptide were recorded, some at high prevalences (up to 43%). Antibodies were also detected to each of the 20 peptides, many at high prevalence (up to 84% of responders), and were directed to both nonrepeat and repeat regions. Immune responses to LSA-3 were detectable even in individuals of less than 5 years of age and increased with age and hence exposure to malaria, although they were not directly related to the level of malaria transmission. Thus, several valuable T- and B-cell epitopes were characterized all along the LSA-3 protein, supporting the antigenicity of this P. falciparum vaccine candidate. Finally, antibodies specific for peptide LSP10 located in a nonrepeat region of LSA-3 were found significantly associated with a lower risk of malaria attack over 1 year of daily clinical follow-up in children between the ages of 7 and 15 years, but not in older individuals.

Entomologie médicale / Parasitologie / Virologie [052]

Fonds IRD [F B010087124]

PAR00003353